title: Solitary plasmacytoma: 10 years' experience at All India Institute of Medical Sciences, New Delhi.
abstract: Plasma cell dyscrasias account for 1% of all malignancies and 10% of hematological malignancies. About 5% of patients with a plasma cell dyscrasia present with either solitary bone plasmacytoma (SBP) or, less commonly, a soft tissue mass, extramedullary plasmacytoma (EMP) of monoclonal plasma cells. In this study we present the clinical features, management and outcome of 60 patients with solitary plasmacytoma, who constituted 5.6% of 1129 patients with plasma cell dyscrasias treated over a 10-year period at All India Institute of Medical Sciences. Median age was 49 years. Fifty-two had SBP and eight had EMP. Forty-nine (82%) patients received radiotherapy with or without surgical excision or chemotherapy. Five-year event-free survival (EFS) and overall survival (OS) were 45.5% and 91%, respectively. Median EFS and OS were 38 and 122 months, respectively. Five-year survival rates in patients who developed multiple myeloma and those who did not were 81% and 100%, respectively. The median time of progression to myeloma was 21 months.
authors.affiliation: Department of Medical Oncology, Dr BRA IRCH, AIIMS, New Delhi, India.
authors.forename: Saphalta
authors.initials: S
authors.lastname: Baghmar
authors.forename: Bidhu K
authors.initials: BK
authors.lastname: Mohanti
authors.forename: Atul
authors.initials: A
authors.lastname: Sharma
authors.forename: Lalit
authors.initials: L
authors.lastname: Kumar
authors.forename: Gaurav
authors.initials: G
authors.lastname: Prakash
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Kumar
authors.forename: Ritu
authors.initials: R
authors.lastname: Gupta
authors.forename: Rajive
authors.initials: R
authors.lastname: Kumar
authors.forename: Vinod
authors.initials: V
authors.lastname: Raina
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D010954:Plasmacytoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome